| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5282 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2758 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1656 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1328 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 332 | 2021 |
| Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison M Ainsworth, M Andersson, K Auckland, JK Baillie, E Barnes, S Beer, ... The Lancet Infectious Diseases 20 (12), 1390-1400, 2020 | 316 | 2020 |
| Viral vectors as vaccine platforms: deployment in sight CS Rollier, A Reyes-Sandoval, MG Cottingham, K Ewer, AVS Hill Current opinion in immunology 23 (3), 377-382, 2011 | 281 | 2011 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 269 | 2021 |
| Viral vectors as vaccine platforms: from immunogenicity to impact KJ Ewer, T Lambe, CS Rollier, AJ Spencer, AVS Hill, L Dorrell Current opinion in immunology 41, 47-54, 2016 | 212 | 2016 |
| Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass R Alcock, MG Cottingham, CS Rollier, J Furze, SD De Costa, M Hanlon, ... Science translational medicine 2 (19), 19ra12-19ra12, 2010 | 176 | 2010 |
| A blood atlas of COVID-19 defines hallmarks of disease severity and specificity DJ Ahern, Z Ai, M Ainsworth, C Allan, A Allcock, B Angus, MA Ansari, ... Cell 185 (5), 916-938. e58, 2022 | 159 | 2022 |
| Upregulation of indoleamine 2, 3-dioxygenase in hepatitis C virus infection E Larrea, JI Riezu-Boj, L Gil-Guerrero, N Casares, R Aldabe, P Sarobe, ... Journal of virology 81 (7), 3662-3666, 2007 | 152 | 2007 |
| CD8+ T effector memory cells protect against liver-stage malaria A Reyes-Sandoval, DH Wyllie, K Bauza, A Milicic, EK Forbes, CS Rollier, ... The Journal of Immunology 187 (3), 1347-1357, 2011 | 146 | 2011 |
| Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein C Rollier, C Sunyach, L Barraud, N Madani, C Jamard, C Trepo, L Cova Gastroenterology 116 (3), 658-665, 1999 | 121 | 1999 |
| Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response C Rollier, E Depla, JAR Drexhage, EJ Verschoor, BE Verstrepen, A Fatmi, ... Journal of virology 78 (1), 187-196, 2004 | 117 | 2004 |
| Natural mutations in a Staphylococcus aureus virulence regulator attenuate cytotoxicity but permit bacteremia and abscess formation S Das, C Lindemann, BC Young, J Muller, B Österreich, N Ternette, ... Proceedings of the National Academy of Sciences 113 (22), E3101-E3110, 2016 | 111 | 2016 |
| Vaccine‐induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD‐1 and chronicity CS Rollier, G Paranhos‐Baccala, EJ Verschoor, BE Verstrepen, ... Hepatology 45 (3), 602-613, 2007 | 108 | 2007 |
| Progress in DNA vaccine for prophylaxis and therapy of hepatitis B A Thermet, C Rollier, F Zoulim, C Trepo, L Cova Vaccine 21 (7-8), 659-662, 2003 | 103 | 2003 |
| Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime–boost immunisation in non-human primates S Capone, A Reyes-Sandoval, M Naddeo, L Siani, V Ammendola, ... Vaccine 29 (2), 256-265, 2010 | 94 | 2010 |
| MAIT cell activation augments adenovirus vector vaccine immunogenicity NM Provine, A Amini, LC Garner, AJ Spencer, C Dold, C Hutchings, ... Science 371 (6528), 521-526, 2021 | 92 | 2021 |
